References in periodicals archive ?
the Company), a clinical stage biopharmaceutical company focused on improving the lives of patients with neurological and kidney diseases associated with low KLK1 levels, announced the publication of positive results from its Phase Ib bridging trial.
All of KLK3 was deleted in individual S8, along with KLK15 and KLK1 (upstream of KLK3), and KLK2 (downstream of KLK3) (see Appendix 5 in the online Data Supplement).
The team also exposed nerve cells isolated from mice to KLK1 or KLK6 in the laboratory, and found the enzymes promoted nerve-cell loss.
DiaMedica), a clinical stage biopharmaceutical company focused on improving lives of patients with neurological and kidney diseases associated with low KLK1 levels, announces its Phase 2 REMEDY clinical trial assessing the safety, tolerability, and markers of therapeutic activity of DM199 (recombinant human KLK1) in patients suffering from acute ischemic stroke.
3B)] (17), D1O1 (deiodinase, iodothyronine, type I) (16), DMN1 (33), VHL (von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase) (35), H1F1A [hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)] (35), KLK10 (kallikrein-related peptidase 10) (31), and KLK1 (kallikrein 1) (36).
In a recent clinical trial, a dose of DM199 administered via IV infusion mimicked the anticipated drug profile of IV-administered urinary KLK1 (Kailikang).
Physiologic functions have been relatively well established for KLK1, 2, and 3.
Because other kallikrein genes, such as KLK1, -2, -5, and -15, also possess a short intron III, we speculated that retention of intron III might be a common splicing event among members of the KLK family.
The human kallikrein gene family was, until recently, thought to include only three members: KLK1, which encodes for pancreatic/renal kallikrein (hK1);  KLK2, which encodes for human glandular kallikrein 2 (hK2); and KLK3, which encodes for prostate-specific antigen (PSA; hK3) (3).
Until recently, it was thought that the human kallikrein gene locus contained only three genes: KLK1,  which encodes for pancreatic renal kallikrein (hK1); KLK2, which encodes for human glandular kallikrein (hK2); and KLK3, which encodes for prostate-specific antigen (PSA; hK3).
The human tissue kallikreins and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library.
Originally, this gene family was thought to contain only three members: KLK1  which encodes for human kallikrein 1 (hK1), also known as pancreatic/renal kallikrein; KLK2, which encodes for hK2; and KLK3, which encodes for hK3, also known as prostate-specific antigen (PSA).
Medical browser ?
- Klieg eye
- Kligman, Albert Montgomery
- Kline, Benjamin S.
- Klinefelter syndrome
- Klinefelter, Harry Fitch
- Klinefelter's syndrome
- Klinger-Ludwig acid-thionin stain for sex chromatin
- klinotactic response
- Klippel disease
- Klippel, Maurice
- Klippel-Feil sequence
- Klippel-Feil syndrome
- Klippel's disease
- Klippel-Trénaunay syndrome
- Klippel-Trenaunay-Weber syndrome
- Kloehn headgear
- Kloepfer, H. Warner
- Klotz, Henri P.
Full browser ?
- Klitgaard, Mogens
- Kliuchevskaia Sopka
- Kliuchevskii, Vasilii
- Kliuchevskii, Vasilii Osipovich
- Kliuev, Nikolai
- Kliuev, Nikolai Alekseevich
- Kliushnikov, Ivan
- Kliushnikov, Ivan Petrovich
- Kliushnikov, Viktor
- Kliushnikov, Viktor Petrovich
- KLK-L2 kallikrein 5
- KLK-L6 kallikrein 14
- KLK8 protein type 1
- KLK8 protein type 2